Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 40

Results For "gene"

3491 News Found

AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility
News | January 12, 2026

AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility

Supports production of AbbVie's current and next-generation immunology and neuroscience medicines


Aragen slashes drug development time with CHOMax platform
News | January 12, 2026

Aragen slashes drug development time with CHOMax platform

CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes


4Moving Biotech bags FDA nod to launch US trial of groundbreaking osteoarthritis therapy
Drug Approval | January 12, 2026

4Moving Biotech bags FDA nod to launch US trial of groundbreaking osteoarthritis therapy

Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function


MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy
Clinical Trials | January 12, 2026

MRM Health scores FDA green light to launch Phase 2b trial of groundbreaking UC therapy

MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms


EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies
Biotech | January 12, 2026

EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies

The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue


NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial
Clinical Trials | January 11, 2026

NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial

The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases


Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
News | January 11, 2026

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients


Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera
News | January 11, 2026

Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories


Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial
Clinical Trials | January 11, 2026

Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial

DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases